D731 MICRO 20 AND D733 MICRO 40 PEDIATRIC ARTERIAL FILTERS
K041061 · Dideco S.P.A. · DTM · May 6, 2004 · Cardiovascular
Device Facts
| Record ID | K041061 |
| Device Name | D731 MICRO 20 AND D733 MICRO 40 PEDIATRIC ARTERIAL FILTERS |
| Applicant | Dideco S.P.A. |
| Product Code | DTM · Cardiovascular |
| Decision Date | May 6, 2004 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 870.4260 |
| Device Class | Class 2 |
| Attributes | Pediatric |
Intended Use
The Dideco D731 MICRO 20 with 20 micron screen and the Dideco D733 MICRO 40 with 40 micron screen are recommended for use in the arterial line of the extracorporeal circuit during any procedure that requires cardiopulmonary bypass. The filters are used to trap and remove gaseous emboli as well as particulate debris that maybe introduced through the arterial line. The device should not be used longer than 6 hours. Contact with blood for longer periods is not advised.
Device Story
Sterile, disposable pediatric arterial filters; D731 (20 micron) and D733 (40 micron). Used in cardiopulmonary bypass circuits; flow rates up to 5.0 L/min. Function: trap/remove gaseous emboli and particulate debris from arterial line perfusate. Operated by perfusionists/clinicians in surgical settings. Output: filtered blood returned to patient. Benefit: reduction of embolic/particulate load during bypass. Design identical to predicate; increased flow rate capacity.
Clinical Evidence
Bench testing only. In vitro studies conducted per FDA guidance (Nov 29, 2000) on aged devices (up to 5 years). Tests included structural/mechanical integrity, blood side pressure drop, flow rate capacity, hemolysis/cell depletion, filtration efficiency, and air handling. Results demonstrated performance comparable to predicate devices.
Technological Characteristics
Materials: same as predicate (no new materials). Filtering media: 20 or 40 micron pore size. Energy source: none (passive). Connectivity: none. Sterilization: ethylene oxide. Fluid path: non-pyrogenic. Form factor: pediatric arterial filter. Flow rate: up to 5.0 LPM.
Indications for Use
Indicated for use in the arterial line of extracorporeal circuits during cardiopulmonary bypass procedures to remove gaseous emboli and particulate debris. Contraindicated for use longer than 6 hours.
Regulatory Classification
Identification
A cardiopulmonary bypass arterial line blood filter is a device used as part of a gas exchange (oxygenator) system to filter nonbiologic particles and emboli (blood clots or pieces of foreign material flowing in the bloodstream which will obstruct circulation by blocking a vessel) out of the blood. It is used in the arterial return line.
Special Controls
*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Arterial Line Blood Filter 510(k) Submissions.”
Predicate Devices
- Dideco D731 Micro 20 Pediatric Arterial Filter with 20 micron screen and Dideco D733 MICRO 40 Pediatric Arterial Filter with 40 micron screen (K945198)
Related Devices
- K033987 — D735 MICRO 20 AND D736 MICRO 40 NEWBORN-INFANT ARTERIAL FILTERS · Dideco S.P.A. · Jan 8, 2004
- K051232 — D731 MICRO 20 PH.I.S.I.O PEDIATRIC ARTERIAL FILTER, D733 MICRO 40 PH.I.SI.O PEDIATRIC ARTERIAL FILTER · Dideco S.R.L. · May 20, 2005
- K112525 — D731 MICRO 27 PH.I.S.I.O. AND D733 MICRO 40 PH.I.S.O. ARTERIAL FILTERS · Parexel International · Sep 29, 2011
- K063255 — D130 PH.I.S.I.O DIDECO KIDS NEONATAL ARTERIAL FILTER WITH 40 MICRON SCREEN PHOSPHORYLCHOLINE COATED · Sorin Group Italia S.R.L. · Jan 11, 2007
- K093986 — AF 620 PH.I.S.I.O., AF 640 PH.I.S.I.O. ARTERIAL FILTERS · Sorin Group Italia S.R.L. · Jan 22, 2010
Submission Summary (Full Text)
{0}------------------------------------------------
**MAY** - 6 2004
SUBMITTER:
CONTACT PERSON:
DATE PREPARED:
DEVICE TRADE NAME:
510(k) SUMMARY
Dideco S.p.A. 86, Via Statale 12 Nord 41037 Mirandola (MO) Italy
Luigi Vecchi Phone: 011 39 0535 29811 Fax: 011 39 0535 25229
April 23, 2004
D731 MICRO 20: Dideco D731 Micro 20 Pediatric Arterial Filter with 20 micron screen (hereafter referred to as D731 MICRO 20) and
D733 MICRO 40: Dideco D733 MICRO 40 Pediatric Arterial Filter with 40 micron screen (hereafter referred to as D733 MICRO 40)
COMMON NAME:
CLASSIFICATION NAME:
PREDICATE DEVICES:
Arterial Filter
Cardiopulmonary Bypass Arterial Line Blood Filter
D731 MICRO 20: Dideco D731 Micro 20 Pediatric Arterial Filter with 20 micron screen and D733 MICRO 40: Dideco D733 MICRO 40 Pediatric Arterial Filter with 40 micron screen (hereafter referred to as D731 and D733 respectively) (K945198).
### DEVICE DESCRIPTION:
The D731 MICRO 20 and D733 MICRO 40 are sterile, non-pyrogenic disposable filters for use in arterial line of the cardiopulmonary bypass circuit with the flow rate not exceeding 5.0 liters/minutes. The D731 MICRO 20 and D733 MICRO 40 are Pediatric Arterial Filters with 20 and 40 micron filter screens designed to remove potentially harmful gaseous emboli, aggregated blood constituents, and particulate debris greater than 20 and 40 microns respectively from the arterial line perfusate. The maximum blood flow rate has been increased to 5.0 liters/minute.
## INDICATION FOR USE:
The Dideco D731 MICRO 20 with 20 micron screen and the Dideco D733 MICRO 40 with 40 micron screen are recommended for use in the arterial line of the extracorporeal circuit during any procedure that requires cardiopulmonary bypass. The filters are used to trap and remove gaseous emboli as well as particulate debris that maybe introduced through the arterial line. The device should not be used longer than b hours. Contact with blood for longer periods is not advised.
{1}------------------------------------------------
# TECHNOLOGICAL CHARACTERISTICS:
The D731 MICRO 20 and the D733 MICRO 40 have the same design features, operating principles and control mechanisms when compared to the D731/D733 predicate devices. The D731 MICRO 20 and the D733 MICRO 40 utilize the same materials, filtering media with the same filter pore size (20 and 40 micron respectively) and the same main blood flow path as the predicate devices.
The D731 MICRO 20 and of the D733 MICRO 40 are, with the exception of the increase of the maximum blood flow rate up to 5.0 LPM, identical to the current MICRO Pediatric series predicate devices. No change of the intended use has been made as result of the extension of the maximum blood flow rate up to 5.0 LPM for both the D731 MICRO 20 and D733 MICRO 40. Both devices share the identical manufacturing process. The arterial filters are ethylene oxide sterilized and have a nonpyrogenic fluid path. They are tor single use only.
# BIOCOMPATIBILITY TEST RESULTS:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-1:1995 and the FDA May 1, 1995 Memorandum on the use of the ISO 10993 standard for biocompatibility testing on the raw materials. Testing was performed on the D731 MICRO 20 and of the D733 MICRO 40 (accelerated aging). The devices were aged up to five years and tested for Hemolysis, Cytotoxicity, In taxes Systemic Toxicity and Mutagenicity, Sterlily, Pyrogenicity and ETO residuals. Package integrity testing was also conducted. The results of the testing met established specifications. No new materials are used in the Pediatric arterial filter as compared to the predicate devices. This 510(k) cross references biocompatibility data previously submitted in D731 MICRO 20 Dideco Pediatric Arterial Filter with 20 micron screen and D733 MICRO 40 Dideco Pediatric Arterial Filter with 40 micron screen 510(k) (K945198).
### IN VITRO TEST RESULTS:
In viro testing was carried out in accordance with the relevant requirements of "Guidance for Cardiopulmonary Bypass Arterial Line Blood Filter 510(k) Submission" Final Guidance for Industry Cated November 29, 2000. These data demonstrate substantial equivalence with the predicate devices and show that the devices are compliant with safety and effectiveness requirements. The device was aged up to 5 years and tested for structural integrity, mechanical integrity, blood side pressure drop, filter flow rate capacity, in vitro hemolysis/cell depletion, filtration efficiency and air handling characteristics. For comparative purposes all tests were performed on sterilized aged devices comparing the D731 MICRO 20 operated at 3.0 LPM vs. the D733 predicate device operated at 5.0 LPM and D731 MCRO 40 operated at 3.0 LPM vs. D733 predicate device operated at 5.0 LPM when applicable. The results of these person net established specifications.
The results of the study showed that the device characteristics of the D731 MICRO 20 vs. D731 predicate device and D733 MICRO 40 vs. D733 predicate device were comparable.
#### CONCLUSIONS:
The results of in vitro studies demonstrate that the D731 MICRO 20 and D733 MICRO devices perform in a manner substantially equivalent to the predicate devices. Biocompatibility and functional tests demonstrate that their performance is equivalent to the D731 and D733 predicate devices, according to their intended use. Additional testing has demonstrated the effectiveness of production techniques assuring the the newborn-infant arterial filters are sterile and non-pyrogenic.
{2}------------------------------------------------
Image /page/2/Picture/2 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an emblem that features a stylized eagle-like bird with three curved lines representing its wings.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAY - 6 2004
Dideco S.P.A. c/o Mr. Barry Sall Parexel International Corp. 195 West Street Waltham, MA 02451-1163
Re: K041061
D731 Micro 20 and D733 Micro 40 Pediatric Arterial Filters Regulation Number: 21 CFR 870.4260 Regulation Name: Filter, Blood, Cardiopulmonary, Arterial Line Regulatory Class: Class II (two) Product Code: DTM Dated: April 23, 2004 Received: April 23, 2004
Dear Mr. Sall:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclesure) to legally marketed predicate devices marketed in interstatc commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 - Mr. Barry Sall
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Myximay-
fv
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the word "dideco" in a bold, sans-serif font. The letters are all lowercase and connected to each other. The color of the text is black, and the background is white. The overall impression is a simple, modern logo.
DIDECO S.p.A.
KO4106 510(k) Number (if known): __
Device Name: D731 MICRO 20, Dideco D731 Micro 20 Pediatric Arterial Filter with 20 micron screen and for the D733 MICRO 40, Dideco D733 Micro 40 Pediatric Arterial Filter with 40 micron screen
Indications for Use:
The Dideco D731 MICRO 20 with 20 micron screen and the Dideco D733 MICRO 40 with 40 micron screen are recommended for use in the arterial line of the extracorporeal circuit during any procedure that requires cardiopulmonary bypass. The filters are used to trap and remove gaseous emboli as well as particulate debris that maybe intrough the arterial line. The device should not be used longer than 6 hours. Contact with blood for longer periods is not advised.
Prescription Use X (Part 21 CFR 801 Subpart D) and/or
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
CMoMarlyn fac BDZ
Digital Sign Off
(Division Sign-Off)
Division of Cardiovascular Device
**510(k) Number** K041661